Our Vision
SynchroBio is dedicated to advancing biotechnology through cutting-edge analytical services for biotech companies. Our mission is to empower our clients with the insights they need to drive innovation and make a meaningful impact in the field of biologics and gene therapy. We are committed to setting new standards of excellence and reliability, positioning ourselves as the go-to partner for biotech analytics.
Why SynchroBio
SynchroBio is a Boston-based contract research organization (CRO) providing advanced analytical services to biotech/biopharmaceutical industry.
Our team brings diverse expertise covering a broad range of modalities at different stages. We are dedicated to maintaining the utmost standards of scientific excellence, data integrity, and professionalism in all our endeavors.
We take a hands-on approach to conducting experiments and data analysis, ensuring meticulous control and precision at every stage of the process.
While maintaining high bar on data quality, our team works hard to expedite project timeline and keep cost within your budget.
Yang Shen
Co-founder & CEO
20 years of biopharma/CRO experience;
Extensive knowledge in assay development, qualification and biophysical characterization;
11 years supporting process development and analytical characterization in Abbott/AbbVie;
Authored CMC sections of multiple IND, IMPD filing documents;
Established PhysChem/Biophysical capabilities and built scientist team in BioAnalytix;
Helped clients with analytical challenges in mAbs, fusion proteins, bispecifics, bioconjugates, AAVs and mRNA/LNPs;
MS in Analytical Chemistry from North Carolina State University.
Hongcheng Liu
CSO
25 years of biopharmaceutical experience;
Recognized expert in analytical development, biologics characterization, and regulatory support;
Led Isembyld's BLA development and filing at Scholar Rock (approved by FDA in Sept 2026);
Held leadership roles at Alexion, Merck, and Abbott, instrumental in the regulatory approvals of Humira and Strensiq;
Expertise spans monoclonal antibodies, Fc-fusion proteins, bispecific antibodies, and peptide-polymer conjugates;
More than 60 peer-reviewed publications;
Ph.D. in Biochemistry from the State University of New York at Albany.
